In new guidelines, an expert panel recommended IHC and PCR for certain cancer types and pointed out knowledge gaps supporting NGS in other settings.
Adaptive Biotechnologies Halts T-Detect Commercialization, Reports 13 Percent Q2 Revenue Growth
Premium
The company realized it is costly to develop single-disease T-Detect assays and is deferring commercialization until a clear path to reimbursement is proven.
The flow cytometry test detects two liver disease biomarkers that can be used to provide information about disease severity.
The firm, which reported a 7 percent drop in Q2 revenues, is laying off roughly 130 workers as it focuses on improving assay quality and scaling its manufacturing.
Nanopath Grabs Spotlight With MDx Platform Providing 15-Minute Results, No Amplification Needed
Premium
Nanopath's platform was the winner of AACC's Disruptive Technology Award, and the firm closed on a $10 million Series A financing round.
Company leaders said that practical steps are being taken to recover from earlier underperformance and support planned growth in NGS and residual disease testing.
The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories.